MERIT MEDICAL SYSTEMS INC (MMSI) Form 8-K — Oct 29, 2026
$MMSIForm 8-KItems 2.02, 7.01, 9.01Filed Oct 29, 2026, 4:07 PM ET0000856982-26-000051Original filing
Merit Medical delivered a strong Q3 2026 beat: revenue of $416.2 million grew 8.4% (9% organic constant currency), GAAP EPS rose 51% to $0.70, and non-GAAP EPS rose 22% to $1.12, with GAAP operating margin expanding to 14.1% from 11.1%. The company raised full-year 2026 guidance, now expecting revenue of $1.635-$1.642 billion and non-GAAP EPS of $4.33-$4.37 (up 13-14% year-over-year), versus prior guidance of $4.25-$4.35. Management cited strong U.S. demand across its Foundational and Therapeutic platforms.
Key figures
- Eps
- 0.7
- Revenue
- 416200000
- Guidance
- FY2026 revenue $1.635-$1.642 billion (up from $1.631-$1.643B); non-GAAP EPS $4.33-$4.37, up 13-14% (raised from $4.25-$4.35)
- Net Income
- 42300000
- Total Debt
- 747500000
- Debt Amount
- 0
- Revenue Yoy
- 8.4%
- Total Assets
- 2924906000
- Cash Position
- 503600000
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 59806000
- Ytd revenue
- 1217000000
- Non gaap eps
- 1.12
- Gaap eps growth
- 51%
- Ytd free cash flow
- 129500000
- Non gaap eps growth
- 22%
- Gaap operating margin
- 14.1% (vs 11.1% prior year)
- Ytd operating cash flow
- 175200000
- Non gaap operating margin
- 21.3% (vs 19.7% prior year)
- Organic cc revenue growth
- 9%
- Solo pace acquisition price
- $45 million cash (plus prior $5 million investments, previously held ~18%)
- Available borrowing capacity
- $697 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.